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Abstract
Background: Rapid emergence of influenza A viruses resistance to anti-influenza drugs has been observed in the past five
years. Our objective was to compare antiviral prescription patterns of ambulatory care providers to patients with a diagnosis
of influenza before and after the 2005–2006 influenza season, which was temporally concordant with the emergence of
adamantane resistance. We also determined providers’ adherence to Centers for Disease Control and Prevention (CDC) 2006
interim treatment guidelines for influenza after the dissemination of guidelines.
Methodology/Principal Findings: We conducted a multi-year cross-sectional analysis using 2002–2006 data from the
national representative ambulatory care surveys, National Ambulatory Medical Care Survey and National Hospital
Ambulatory Medical Care Survey. Our main outcome measure was prescription of any anti-influenza pharmaceutical
medication, including amantadine, rimantadine, oseltamivir, and zanamivir. Analyses were performed using procedures
taking into account the multi-stage survey design and weighted sampling probabilities of the data source. Overall, there
were 941 visits to U.S. ambulatory care providers for which the diagnosis of influenza was made, representing 12,140,727
visits nationally. Antiviral drugs were prescribed in 21.7% of visits. Even though prescription rates were not significantly
different by influenza season (2001–02: 26.4%; 2002–03: 11.2%; 2003–04: 16.5%; 2004–05: 18.0%; 2005–06: 35.8%; 2006–07:
46.5%, p=0.061), significantly higher prescription rates were observed in the high adamantane resistance period (18.7%
versus 37.0%, p=0.023), and after the announcement of the 2006 guidelines (18.5% versus 38.8%, p=0.032). Use of
adamantanes decreased over time, in that they were commonly used during influenza seasons 2001–03 (60.1%), but used
much less frequently during seasons 2003–05 (31.9%), and used rarely after high adamantane resistance emerged (2.2%)
(p,0.001). Adherence to 2006 guidelines was 97.7%. After March 2006, no prescriptions for adamantanes were given to
patients with a diagnosis of influenza.
Conclusions/Significance: In this nationally representative study of U.S. ambulatory care visits, we found a complete
absence of the use of adamantanes in all ambulatory care settings after March 2006, closely corresponding to release of the
2006 CDC interim guidelines. Adherence to such practice is an essential element for control and prevention of influenza,
especially during the era of emergence of resistance to anti-viral drugs.
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Introduction
Each year, Americans make more than 20 million clinic visits
per year for influenza. Of these, only 19% of visits receive antiviral
prescription from their medical providers [1]. This low rate of
antiviral treatment observed in practice may hamper public health
efforts to minimize mortality, shorten the course of disease, and
decrease transmission in the communities for the current novel
influenza A (H1N1) [2] or future pandemics.
Rapid emergence of influenza A viruses resistance to anti-
influenza drugs has been observed in the past five years. First,
resistance of seasonal influenza A viruses to once first-line anti-
influenza drugs, the adamantanes (amantadine and rimantadine)
emerged in the United States, with resistance rates increasing from
14.5% during the 2004–2005 influenza season, to 92.3% during
the 2005–2006 season [3]. In response, the US Centers for Disease
Control and Prevention (CDC) recommended that adamantanes
should not be used for treatment or prophylaxis of influenza on
January 14, 2006 in the interim treatment guidelines [4]. Since
that time, after only 3 influenza seasons, rates of oseltamivir-
resistant to seasonal influenza A virus (H1N1) stains have risen
from 12% to nearly 99% [5]. Accordingly, the CDC now
recommends that when influenza A (H1N1) virus infection or
exposure is suspected, zanamivir or a combination of oseltamivir
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alone [6]. Only a few months later in the early summer of 2009,
the first influenza pandemic in more than 40 years has arrived [2].
The CDC recommends use of oseltamivir or zanamivir for the first
line treatment and/or prevention of infections since the circulating
strain is resistant to the adamantanes [7]. Few cases of oseltamivir-
resistance strains of novel influenza A (H1N1) have been
documented [8].
Timely and effective dissemination of these interim treatment
guidelines for influenza from CDC to medical providers is crucial
to prescribe appropriate antivirals for patients with confirmed or
suspected influenza. In the past decade, CDC has disseminated
treatment information (which could be a CDC Health Advisory,
Health Alert, or Health Update) via CDC Health Alert Network
(HAN) to state and local health officers, public information
officers, epidemiologists, state laboratory directors, weapons of
mass destruction coordinators, HAN coordinators, as well as
public health associations and clinician organizations [9]. Few, if
any studies, have examined U.S. medical providers’ antiviral drug
prescription usage patterns and trends for patients with a diagnosis
of influenza, before and after the emergence of drug resistance.
Notably, studies have been conducted evaluating provider
adherence with CDC treatment guidelines for other infectious
diseases, with rates varying significantly across syndromes, i.e. 30%
for pelvic inflammatory disease [10] and upper respiratory
infections [11], 50%–85% for acute epididymitis [12], and over
97% for chlamydia [13].
Utilizing the national representative ambulatory medical care
surveys National Ambulatory Medical Care Survey (NAMCS) and
the National Hospital Ambulatory Medical Care Survey
(NHAMCS) [14] by National Center for Health Statistics, CDC,
we compared antiviral prescription patterns of ambulatory
medical care providers for patient visits with a diagnosis of
influenza before and after the 2005–2006 influenza season, which
was temporally concordant with the emergence of adamantane
resistance. We also determined medical provider’s adherence to
CDC 2006 interim treatment guidelines for influenza after the
dissemination of the CDC guidelines.
Materials and Methods
We conducted a multi-year cross-sectional analysis using 2002–
2006 data from three national representative ambulatory medical
care surveys. The data from these three surveys include weighted
samples of U.S. patient visits to non-federally employed office-
based physicians from the NAMCS, U.S. emergency department
(ED) visits from the ED component of the NHAMCS, and U.S.
hospital outpatient visits, from the outpatient component of
NHAMCS. NAMCS and NHAMCS data were collected by a
standard survey form collected by physicians, office workers, or
hospital staff. The multi-stage probability sampling scheme, the
visit, and the reliability of coding and data entry for NAMCS and
NHAMCS have been detailed elsewhere [15]. The NAMCS and
NHAMCS data are publicly accessible and deidentified. Accord-
ingly, the Johns Hopkins University Medicine institutional review
board (IRB) deemed our study as nonhuman-subjects research,
exempt from IRB review.
In this study, we employed the data collected by the NAMCS
and NHAMCS, including demographic characteristics, diagnoses,
and medications of the patient visits. Up to three diagnoses were
recorded as free text and coded centrally by Constella Group, Inc.
and subject to quality control procedures [16]. A visit with a
diagnosis of influenza was defined as International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)
codes of 487, 487.0, 487.1 or 487.8. All visits with a diagnosis of
influenza during the study period were included for analysis. Six
(in 2002) or eight (2003–2006) medications that were ordered or
provided were collected and coded in the data set. Our main
outcome measure was prescription of any anti-influenza pharma-
ceutical medication, including amantadine, rimantadine, oselta-
mivir, and zanamivir. A visit with a prescription of anti-influenza
drug by providers was defined as medications matching for
NAMCS and NHAMCS drug entry codes for amantadine
(Symmetrel), rimantadine (Flumadine), oseltamivir (Tamiflu), and
zanamivir (Relenza).
NAMCS and NHAMCS data from the years 2002–2006 were
merged for data analysis. A sample weight that considers selection
probability, nonresponse adjustment, and ratio adjustment for
different total sample size each year is assigned for each patient
visit to generate unbiased national estimates of ambulatory
medical care visits. Although the sampling fraction is relatively
small, the weighted numbers calculated by the method suggested
by the CDC represent unbiased national estimates of the US
ambulatory medical care population. Study period was catego-
rized into 6 influenza seasons beginning October 1 to the end of
September of the following year. In addition, study periods were
further categorized into (1) pre-high adamantane resistance period
versus high adamantane resistance period, based on the time when
adamantane resistance rates reached over 90% [3], i.e. October
2005, or (2) before versus after the announcement of the 2006
interim treatment guidelines, based on the time of release of the
2006 CDC interim treatment guidelines [4], i.e. January 14, 2006.
Adherence to the 2006 CDC interim treatment guidelines was
defined as no adamantane prescribed to patients with a diagnosis
of influenza, following the announcement of the treatment
guidelines on January 14, 2006.
Descriptive demographic analyses of patient visits with a
diagnosis of influenza, and patient visits with antiviral medications
for influenza, were performed. Comparison of proportions, e.g.
prescription rate in pre-high adamantane resistance period versus
that in high adamantane resistance period, was assessed by chi-
square test. All p values were 2-sided, with p,0.05 considered
significant. Multivariate analyses and estimation of 95% CI were
not conducted if the sample size of interest was less than 30, as the
estimate is considered unreliable under NAMCS and NHAMCS
analysis recommendations [17]. Analyses were performed using
SAS 9.1 SURVEYFREQ procedure which takes into account the
multi-stage survey design and weighted sampling probabilities of
the data source (SAS version 9.1, SAS Institute Inc., Cary, North
Carolina). Results were reported as weighted frequencies,
percentages, and 95% confidence intervals (CI).
Results
Overall, during 2002–2006, there were 941 visits to U.S.
ambulatory care providers for which the diagnosis of influenza was
made in the sample, representing 12,140,727 (95% CI:
10,116,136–14,165,318) patient visits nationally, or 0.22% (95%
CI: 0.18–0.25) of all visits over this time. Demographics, type of
ambulatory care, and influenza season in which patient visits
resulted in a diagnosis of influenza were summarized in Table 1.
Office-based physician visits represented the highest volume
(9,459,918 visits, 77.9%), followed by ED visits (1,872,200 visits,
15.4%) and outpatient visits (808,609 visits, 6.7%). Among visits
with a diagnosis of influenza, those which occurred during periods
of high adamantane resistance, and after the announcement of
2006 CDC interim treatment guidelines accounted for 18.7% and
15.3% of all visits, respectively.
Prescription for Flu Patients
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of visits (weighted 2,629,129 visits; 95% CI: 1,886,292–3,
371,966). Prescription rates by each demographic character-
istic and type of ambulatory care were summarized in Table 1.
Although EDs had the highest prescription rate, (29.0%), there
was no statistical difference observed by type of ambulatory
care setting (p.0.05). In addition, there were no statistical
differences in prescription rates by demographic variables
except by the U.S. region. Even though, prescription rates
were not significantly different by influenza season, signifi-
cantly higher antiviral drug prescription rates were observed in
the high adamantane resistance period, and after the
announcement of the 2006 CDC interim treatment guidelines
(Table 2).
Table 1. National estimates of ambulatory medical care visits with a diagnosis of influenza and the antiviral prescription by
demographics in the United States, 2002–2006.
Characteristics % of National estimated visits (95% CI) p-value
Diagnosis of Influenza
(N=12,140,727)
Antiviral Prescription in Visits
with Influenza in specific subgroup
Overall - 21.6 (16.7–26.6)
Age group, y 0.225
0–9 37.9 (29.5–44.2) 19.3 (9.3–29.3)
10–19 17.0 (13.1–21.0) 31.1 (17.1–45.1)
20–29 9.1 (6.4–11.9) 19.2 (9.7–28.6)
30–39 13.1 (8.5–17.8) 29.1 (13.3–44.8)
40–49 10.4 (7.3–13.6) 21.0 (NA)
50–59 3.8 (1.7–6.0) 9.1 (NA)
$60 9.5 (6.4–12.7) 11.8 (NA)
Sex 0.548
Female 54.1 (47.8–60.4) 20.3 (13.6–27.0)
Male 45.9 (39.6–52.2) 23.2 (16.4–30.1)
Race 0.168
White 83.6 (76.9–90.3) 21.2 (16.5–25.9)
Black 11.8 (5.2–18.3) 13.6 (2.6–24.6)
Other 4.7 (2.0–7.3) 50.2 (NA)
Ethnicity*
Hispanic 11.6 (7.9–15.3) 21.9 (NA) 0.985
Non-Hispanic 83.8 (78.3–89.3) 21.8 (16.8–26.7)
Insurance Type
Private 61.2 (56.2–66.2) 18.8 (14.0–23.5) 0.052
Public 25.8 (20.8–30.8) 16.2 (7.6–24.8)
Self-Pay 5.5 (2.9–8.1) 71.7 (NA)
Other/Unknown 7.5 (4.5–10.5) 27.2 (NA)
Urban Status 0.337
MSA{ 85.1 (77.7–92.5) 20.4 (15.0–25.8)
Non-MSA 14.9 (7.5–22.3) 28.6 (12.4–44.9)
US Region 0.004
Northeast 18.6 (13.4–23.8) 12.3 (NA)
Midwest 18.4 (16.2–24.2) 10.8 (5.2–16.4)
South 43.2 (34.5–52.0) 31.0 (21.1–40.8)
West 19.7 (14.5–25.0) 20.1 (9.7–30.6)
Ambulatory Care 0.287
Emergency Department 15.4 (12.5–18.3) 29.0 (21.1–36.9)
Outpatient 6.7 (3.2–10.1) 18.9 (7.2–30.7)
Physician Office 77.9 (73.6–82.2) 20.4 (13.9–27.0)
*Ethnicity missing for 4.7% of sample.
{MSA: Metropolitan Statistical Area.
{NA: Not applicable due to the sample size of interest in the surveys was less than 30, as the estimate is considered unreliable under NAMCS and NHAMCS analysis
recommendations.
doi:10.1371/journal.pone.0008945.t001
Prescription for Flu Patients
PLoS ONE | www.plosone.org 3 January 2010 | Volume 5 | Issue 1 | e8945Numbers of antiviral prescriptions for influenza in U.S.
ambulatory care visits resulting in a diagnosis of influenza were
summarized in Table 3. Use of adamantanes decreased over time,
in that they were commonly used during influenza seasons 2001–
02 and 2002–03 (60.1%), but were used much less frequently
during seasons 2003–04 and 2004–05 (31.9%), and were used
rarely after high adamantane resistance emerged (2.2%) (p,0.001)
(Figure 1). In contrast, oseltamivir accounted for only 36% of total
antiviral prescription during the influenza season 2001–02, but
increased over time, becoming the predominant anti-influenza
prescription in all three ambulatory care settings during the high
adamantane resistance period, i.e. after October 2005 (97.8%;
95% CI: 93.9–100%). There were no statistical differences in anti-
influenza prescriptions by type of ambulatory care or by other
demographic variables, before or during high adamantane
resistance period (data not shown). Therefore, a multivariate
analysis was not performed on use of adamantanes or oseltamivir
and time.
Table 2. National estimates of ambulatory medical care visits with a diagnosis of influenza and the antiviral prescription by
influenza season, high adamantane resistance period, and announcement of 2006 CDC guidelines in the United States, 2002–2006.
Characteristics % of National estimated visits (95% CI) p-value
Diagnosis of Influenza
(N=12,140,727)
Antiviral Prescription in Visits
with Influenza in specific subgroup
Influenza Season 0.061
2001–02 (Jan 2002–Sep 2002) 20.3 (11.1–29.4) 26.4 (10.4–42.3)
2002–03 (Oct 2002–Sep 2003) 18.3 (10.7–26.0) 11.2 (NA)
2003–04 (Oct 2003–Sep 2004) 24.3 (17.7–30.9) 16.5 (4.8–28.2)
2004–05 (Oct 2004–Sep 2005) 18.4 (12.3–24.5) 18.0 (8.9–27.1)
2005–06 (Oct 2005–Sep 2006) 16.5 (11.8–21.2) 35.8 (24.5–47.1)
2006–07 (Oct 2006–Dec 2006) 2.2 (NA) 46.5 (NA)
High Adamantane Resistance Period 0.023
No (Before October 2005) 81.3 (76.5–86.1) 18.1 (12.7–23.5)
Yes (After October 2005) 18.7 (13.9–23.5) 37.0 (24.8–49.3)
2006 CDC Guidelines (Jan. 14 2006) 0.032
Before Announcement 84.7 (80.0–89.3) 18.5 (13.4–23.7)
After Announcement 15.3 (10.7–20.0) 38.8 (24.8–52.8)
*NA: Not applicable due to the sample size of interest in the surveys was less than 30, as the estimate is considered unreliable under NAMCS and NHAMCS analysis
recommendations.
doi:10.1371/journal.pone.0008945.t002
Table 3. Numbers of antiviral prescription for influenza in U.S. ambulatory care visits with a diagnosis of influenza during 2002–
2006.
Study Periods
Visits (%) with Antiviral
Prescription (N=2,629,129)
No.(%) Prescription of
Adamantanes in Each Period
No. (%) Prescription of
Oseltamivir in Each Period p-value
Influenza Seasons 0.0020{
2001–02 (Jan 2002–Sep 2002) 648,207 (20.3%) 411,447 (63.5%) 235,567 (36.3%)
*
2002–03 (Oct 2002–Sep 2003) 249,842 (18.3%) 128,230 (51.3%) 119,928 (48.0%)
*
2003–04 (Oct 2003–Sep 2004) 487,631 (24.3%) 137,420 (28.2%) 350,211 (71.8%)
2004–05 (Oct 2004–Sep 2005) 402,208 (18.4%) 146,331 (36.4%) 255,877 (63.6%)
2005–06 (Oct 2005–Sep 2006) 718,061 (16.5%) 18,843 (2.6%) 699,218 (97.4%)
2006–07 (Oct 2006–Dec 2006) 123,180 (2.2%) 0 (0%) 123,180 (100%)
High Adamantane Resistance Period 0.0001
No (Before October 2005) 1,787,888 (81.3%) 823,428 (46.1%) 961,583 (53.8%)
*
Yes (After October 2005) 841,241 (18.7%) 18,843 (2.2%) 822,398 (97.8%)
2006 CDC Guidelines (Jan. 14 2006) 0.0008
Before Announcement 1,906,290 (84.7%) 825,605 (43.3%) 1,077,808 (56.5%)
*
After Announcement 722,839 (15.3%) 16,666 (2.3%) 706,173 (97.7%)
*Zanamivir was prescribed, therefore, percentages of prescription in these horizontal rows were not added up to 100%.
{P-value cannot be computed for all influenza seasons because at least one table cell has 0 frequency (season 2006–07). P-value was calculated based on the
comparison of influenza season 2001–02 to season 2005–06.
doi:10.1371/journal.pone.0008945.t003
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guidelines was 97.7% (95% CI: 93.0%–100%). After March 2006,
no prescriptions for adamantanes were given to ambulatory-care
patients with a diagnosis of influenza (last prescription in the
dataset: office-based physician visit: February 2005; ED visit:
February 2006; outpatient visit: March 2006).
Discussion
In this nationally representative study, we found that the use of
adamantanes markedly decreased after the influenza 2002–2003
season, and were rapidly replaced by oseltamivir as the
predominantly prescribed anti-influenza drug therapy in U.S.
non-federally employed office-based physician, ED, and outpatient
visits. The major shift occurred during the early influenza 2005–
2006 season, paralleling the rapid emergence of adamantane
resistance of influenza A viruses seen in both Asia [18] and the
U.S. [3]. We also identified a complete absence of adamantane
prescriptions in all ambulatory medical care settings after March
2006, which closely corresponded to release of the CDC interim
guidelines for use of antiviral agents for 2005–06 influenza season.
Both findings suggest that the antiviral prescribing practice for
influenza treatment or prophylaxis among U.S. ambulatory
medical care providers was closely in line with the most up-to-
date global epidemiological resistance patterns, as well as the CDC
recommendations, which provides encouraging news regarding
medical provider’s capacity to adhere with evolving changes in
antiviral treatment recommendations, particularly relevavant to
the current circulating novel H1N1 influenza virus, as well as other
potential emerging influenza pandemics.
Prescription patterns and compliance with existing CDC
treatment guidelines vary by diseases. The reasons for the
variation are beyond the scope of our study. However, potential
contributors include severity of disease, individual provider
perception regarding the individual patient and public health
impact of effective treatment/post-exposure prophylaxis, the
intensity of media reporting, and the ease of implementation.
Together these factors could contribute to the significant
differences between the nearly perfect provider adherence
observed for CDC treatment guidelines for influenza, versus that
seen for PID, upper respiratory infections, and acute epididymitis
[10,11,12]. One infectious disease in which clinician adherence
with CDC guidelines is also high is genital chlamydial infection,
where, effective dissemination of updates, implementation of
electronic order-entry systems, and national continuing medical
education efforts have been reported to increase rates of
compliance in at least 2 large managed care organizations [13].
Since patients with suspected influenza visit a variety of
ambulatory care settings in the U.S., timely and concentrated
electronic communication messages and interaction between the
CDC and each medical society and institution, as well as effective
dissemination from the society or institution to its own members is
likely critical for ensuring adherence with the most up to date
treatment guidelines during a pandemic. Individual institutional
utilization of modern information technology, e.g. electronic
medical record system, is also certainly important in promotion
of new treatment guidelines and will aid in minimizing
inappropriate use of treatment regimen in the case that guidelines
are modified [19,20]. To what extent these interventions
contributed to the high rates of compliance seen here is not
known but warrants further study.
The NAMCS and NHMACS databases do not have a specific
focus on adamantanes prescriptions and potential emergence of
resistance, as this is not the primary purpose of these survey tools.
Accordingly, associated factors not collected in NAMCS and
NHAMCS, such as virus subtype coverage (i.e., influenza A versus
B), medication side effects, prior antiviral prescriptions, and
clinician’s knowledge of emerging resistance, may have contrib-
uted to the observed trends. In addition, other factors, e.g. ease of
antiviral medication administration, need to adjust dosage
according to age and renal function, and prior antiviral
prescriptions may have contributed to the observed temporal
Figure 1. Prescription of anti-influenza agents for patient visits with a diagnosis of influenza in US ambulatory care including
emergency department visits, outpatient visits and physician office visits, by antiviral drug, influenza season 2001–2007.
a The time
CDC declared interim guidelines for use of anti-influenza drugs.
b The start of high adamantane resistance period.
c Adamantanes include amantadine
and rimantadine.
doi:10.1371/journal.pone.0008945.g001
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ambulatory care settings. Finally, ICD-9-CM coding, which is not
a gold standard for influenza case reporting, was used to define
cases of influenza rather than other potentially more valid
standards – e.g. laboratory confirmed tests.
In conclusion, our study demonstrated extremely high adher-
ence to the most current national treatment recommendations for
influenza among non-federal-employed ambulatory medical care
providers in the U.S. Adherence to such practice is an essential
element for control and prevention of influenza, especially during
the era of emergence of resistance to anti-viral drugs.
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